Results 21 to 30 of about 819,276 (191)

EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS [PDF]

open access: yesAl-Azhar Journal of Pharmaceutical Sciences, 2023
Due to its powerful anticancer characteristics, the heterocyclic quinazoline has attracted a lot of interest in cancer research. Several cancer types, including lung, breast, colon, ovarian, and prostate cancers, have shown promise in response to ...
Abdelsalam Ouf   +3 more
doaj   +1 more source

Nanocatalyzed Synthetic Approach for the Quinazolinone and Quinazoline Derivatives: A Review (2015 – Present) [PDF]

open access: yes, 2023
Due to their diverse chemical reactivities and essential range of biological action, quinazolines and their derivatives rank among the most significant heterocyclic compounds.
Lav Kush Kumar Vishwakarma   +3 more
core   +1 more source

REVIEW ON THE SIGNIFICANCE OF QUINAZOLINE DERIVATIVES AS BROAD SPECTRUM ANTI-CANCER AGENTS. [PDF]

open access: yesAl-Azhar Journal of Pharmaceutical Sciences, 2021
Cancer is one of the major causes of human mortality worldwide. A number of approved antineoplastic medications and treatment regimens are already working in the field, and several new compounds are in different phases of clinical trials.
Mohamed El-Zahabi
doaj   +1 more source

COMPUTATION DESIGN OF QUINAZOLINE-4(3H)-ON DERIVATIVES AS CYCLOOXYGENASE-2 (COX-2) INHIBITOR

open access: yesJurnal Farmasi Sains dan Praktis, 2021
The 3-(benzylideneamino)-2-(2,4-dichlorophenyl)-quinazoline-4(3H)-ones (BDCQ) are compounds developed as anticancer drugs and quinazolines. The activity and bioavailability of BDCQ derivatives as anticancer compounds that inhibit COX-2 can be predicted ...
Anita Puspa Widiyana
doaj   +1 more source

Design and biological evaluation of 3-substituted quinazoline-2,4(1H,3H)-dione derivatives as dual c-Met/VEGFR-2-TK inhibitors

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2023
The dual c-Met/vascular endothelial growth factor receptor 2 (VEGFR-2) TK inhibition is a good strategy to overcome therapeutic resistance to small molecules VEGFR-2 inhibitors.
Abdelfattah Hassan   +6 more
doaj   +1 more source

Some novel hybrid quinazoline-based heterocycles as potent cytotoxic agents

open access: yesResearch in Pharmaceutical Sciences, 2022
Background and purpose: In this study, some new cytotoxic hybrid structures were synthesized by combining pyrazolinone and imidazolinone rings with quinazoline pharmacophores. Experimental approach: The benzoxazinone, pyrazolo-quinazoline fused ring, and
Mahla Malekzadeh   +5 more
doaj   +1 more source

Quinazoline analogues as cytotoxic agents; QSAR, docking, and in silico studies

open access: yesResearch in Pharmaceutical Sciences, 2021
Background and purpose: Synthesis and investigation of pharmacological activity of novel compounds are time and money-consuming. However, computational techniques, docking, and in silico studies have facilitated drug discovery research to design ...
Leila Emami   +4 more
doaj   +1 more source

Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy. [PDF]

open access: yesFront Chem, 2021
Cancer diseases remain major health problems in the world despite significant developments in diagnostic methods and medications. Many of the conventional therapies, however, have limitations due to multidrug resistance or severe side effects.
Wdowiak P   +5 more
europepmc   +2 more sources

Susceptibility of different organisms to quinazoline derivatives.

open access: yes, 2020
Susceptibility of different organisms to quinazoline derivatives.
Natalia Monakhova (8351475)   +11 more
core   +1 more source

Current Progress in Quinazoline Derivatives as Acetylcholinesterase and Monoamine Oxidase Inhibitors

open access: yes, 2021
Among the N-containing heterocyclic compounds, quinazoline-4-(3H)-one derivatives have been the center of attraction of medicinal and synthetic chemists due to their excellent versatility in biological activities that are witnessed by many approved drugs
Rehuman N. A.   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy